[Rhabdomyolysis with acute renal failure and malignant neuroleptic syndrome]. 1982

D Kleinknecht, and A Parent, and P Blot, and G Bochereau, and P Y Lallement, and J L Pourriat

Seven episodes of rhabdomyolysis with acute renal failure (ARF) have been observed in 6 patients treated with various short-acting tranquilizers and antidepressants. Clinical features usually included severe hyperthermia, diffuse hypertonicity with or without coma, circulatory failure or unstable blood pressure, and often acute respiratory failure. Serum CPK were always elevated. The type of ARF was prerenal failure without oliguria in 5/7 episodes, and acute tubular necrosis in 2/7 episodes, requiring hemodialyses in one patient. Three patients died. In any case, the tranquilizers and antidepressants responsible for this syndrome were stopped, and electrolyte disorders and acidosis were corrected. Associated acute circulatory failure, septicemia and/or acute hepatic failure required prompt therapy, and artificial ventilation was required in 4 instances. The further use of phenothiazines, butyrophenones, sulpiride and their derivatives should be avoided in any patient having developed such an accident, whose pathophysiology is similar to that described in malignant hyperthermia of various origin.

UI MeSH Term Description Entries
D008297 Male Males
D008305 Malignant Hyperthermia Rapid and excessive rise of temperature accompanied by muscular rigidity following general anesthesia. Hyperpyrexia, Malignant,Hyperthermia, Malignant,Malignant Hyperpyrexia,Anesthesia Related Hyperthermia,Hyperthermia of Anesthesia,Anesthesia Hyperthermia,Hyperthermia, Anesthesia Related,Malignant Hyperpyrexias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009135 Muscular Diseases Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE. Muscle Disorders,Myopathies,Myopathic Conditions,Muscle Disorder,Muscular Disease,Myopathic Condition,Myopathy
D003402 Creatine Kinase A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins. Creatine Phosphokinase,ADP Phosphocreatine Phosphotransferase,ATP Creatine Phosphotransferase,Macro-Creatine Kinase,Creatine Phosphotransferase, ATP,Kinase, Creatine,Macro Creatine Kinase,Phosphocreatine Phosphotransferase, ADP,Phosphokinase, Creatine,Phosphotransferase, ADP Phosphocreatine,Phosphotransferase, ATP Creatine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major

Related Publications

D Kleinknecht, and A Parent, and P Blot, and G Bochereau, and P Y Lallement, and J L Pourriat
September 1996, Recenti progressi in medicina,
D Kleinknecht, and A Parent, and P Blot, and G Bochereau, and P Y Lallement, and J L Pourriat
September 1998, The Mount Sinai journal of medicine, New York,
D Kleinknecht, and A Parent, and P Blot, and G Bochereau, and P Y Lallement, and J L Pourriat
May 2008, Progress in neuro-psychopharmacology & biological psychiatry,
D Kleinknecht, and A Parent, and P Blot, and G Bochereau, and P Y Lallement, and J L Pourriat
January 1991, Revista espanola de anestesiologia y reanimacion,
D Kleinknecht, and A Parent, and P Blot, and G Bochereau, and P Y Lallement, and J L Pourriat
July 2002, Renal failure,
D Kleinknecht, and A Parent, and P Blot, and G Bochereau, and P Y Lallement, and J L Pourriat
October 1995, Orvosi hetilap,
D Kleinknecht, and A Parent, and P Blot, and G Bochereau, and P Y Lallement, and J L Pourriat
January 1994, Journal of the American Society of Nephrology : JASN,
D Kleinknecht, and A Parent, and P Blot, and G Bochereau, and P Y Lallement, and J L Pourriat
March 2017, Psychiatria Danubina,
D Kleinknecht, and A Parent, and P Blot, and G Bochereau, and P Y Lallement, and J L Pourriat
November 1992, Hinyokika kiyo. Acta urologica Japonica,
D Kleinknecht, and A Parent, and P Blot, and G Bochereau, and P Y Lallement, and J L Pourriat
October 1994, Nihon Jinzo Gakkai shi,
Copied contents to your clipboard!